A phase 1b/2a study of fezagepras for patients with high triglyceride levels (hypertriglyceridemia)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 03 Jun 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 May 2021 According to a Liminal BioSciences media release, based on the interim pharmacokinetic results from the ongoing Fezagepras multiple ascending dose (MAD) study, the company has decided to stop its plans to move fezagepras into a phase Ia/IIb study in Hypertriglyceridemia.
28 May 2021 Status changed from planning to discontinued, according to Liminal BioSciences media release.
17 May 2021 According to a Liminal BioSciences media release, the company expects to initiate this study in the 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com